专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US07785627B2 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative 有权
标题翻译：含有双胍和噻唑烷二酮衍生物的药物制剂
公开(公告)号：US07785627B2
公开(公告)日：2010-08-31
申请号：US10664803
申请日：2003-09-19
申请人： Unchalee Kositprapa , Robert I. Goldfarb , John Cardinal , Avinash Nangia
发明人： Unchalee Kositprapa , Robert I. Goldfarb , John Cardinal , Avinash Nangia
IPC分类号： A61K9/14 , A61K9/22 , A61K31/426 , A61K31/155
CPC分类号： A61K9/209 , A61K9/0004 , A61K9/282 , A61K31/155 , A61K31/425 , A61K31/426 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
摘要翻译：本文公开和描述了包含与包含噻唑烷二酮衍生物的第二组分组合的抗高血糖药物的控释组分的药物剂型。

32. 发明申请

US20090124563A1 ORAL EXTENDED-RELEASE COMPOSITION 有权
标题翻译：口服延长释放组成
公开(公告)号：US20090124563A1
公开(公告)日：2009-05-14
申请号：US12327477
申请日：2008-12-03
申请人： Boying Li , Avinash Nangia , Monte Browder
发明人： Boying Li , Avinash Nangia , Monte Browder
IPC分类号： A61K31/7028 , A61P31/04
CPC分类号： A61K9/2077 , A61K9/1652 , A61K9/5084
摘要： The invention is directed to controlled release formulations containing drugs which are preferably considered sparingly soluble to insoluble and which are suitable for administration to a patient in need of treatment related thereto, and methods of manufacturing the same.
摘要翻译：本发明涉及含有药物的控制释放制剂，其优选被认为是微溶于不溶性的并且适用于需要与之有关的治疗的患者的给药及其制备方法。

33. 发明申请

US20080260824A1 Bioadhesive Rate-Controlled Oral Dosage Formulations 审中-公开
标题翻译：生物粘合剂速率控制的口服剂型
公开(公告)号：US20080260824A1
公开(公告)日：2008-10-23
申请号：US11661540
申请日：2005-08-29
申请人： Avinash Nangia , Jules Jacob , Peyman Moslemy
发明人： Avinash Nangia , Jules Jacob , Peyman Moslemy
IPC分类号： A61K9/22 , A61K9/00 , A61K31/52 , A61K31/19 , A61K31/4436 , A61P43/00 , A61K31/17 , A61K9/14 , A61K9/32
CPC分类号： C08F8/32 , A61K9/0004 , A61K9/006 , A61K9/0065 , A61K9/204 , A61K9/2077 , A61K9/2081 , A61K9/2086 , C08G63/91 , C08G63/912 , C09J167/00 , C09J167/04 , C08F222/06
摘要： The present invention relates to a bioadhesive drug delivery system (BIOadhesive Rate controlled Oral Dosage (BIOROD) formulation) in which a drug containing core either alone or coated with a rate controlling membrane system is enveloped on its circumference by a bioadhesive coating, thereby yielding a monolithic system that allows for drug release in a regulated manner. Also described herein are polymers with improved bioadhesive properties and methods for improving bioadhesion of polymers.
摘要翻译：本发明涉及一种生物粘附药物递送系统（BIOadhesive Rate controlled Oral Dosage（BIOROD）配方），其中单独或用速率控制膜系统涂覆的药物的核心通过生物粘附剂包被在其圆周上，从而产生整体式系统允许以规定的方式释放药物。本文还描述了具有改进的生物粘附性质的聚合物和用于改善聚合物生物粘附的方法。

34. 发明授权

US07314640B2 Formulation and process for drug loaded cores 有权
标题翻译：药物加载核心的制剂和工艺
公开(公告)号：US07314640B2
公开(公告)日：2008-01-01
申请号：US10617456
申请日：2003-07-11
申请人： Mongkol Sriwongjanya , Samuel Yuk , Avinash Nangia
发明人： Mongkol Sriwongjanya , Samuel Yuk , Avinash Nangia
IPC分类号： A61K9/14 , A61K9/16 , A61K9/48 , A61K9/20 , A61K9/22
CPC分类号： A61K9/1676 , A61K9/2077 , A61K31/00 , A61K31/137
摘要： The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core.
摘要翻译：本发明涉及美托洛尔及其药学上可接受的盐的控释丸，其使用水溶性或水溶胀性惰性起始种子或核心。

35. 发明申请

US20070281007A1 Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs 审中-公开
标题翻译：高渗透性，高溶解度药物的黏膜粘膜口服制剂
公开(公告)号：US20070281007A1
公开(公告)日：2007-12-06
申请号：US11574407
申请日：2005-08-29
申请人： Jules Jacob , Peyman Moslemy , Avinash Nangia , Ze'ev Shaked , Mark Kreitz
发明人： Jules Jacob , Peyman Moslemy , Avinash Nangia , Ze'ev Shaked , Mark Kreitz
IPC分类号： A61K9/32 , A61K31/155 , A61K31/195 , A61K9/50 , A61K9/52 , A61K31/343 , A61K9/14
CPC分类号： A61K9/006 , A61K9/2086 , A61K9/2846 , A61K31/74
摘要： Solid oral dosage formulations, such as tablet, mini-tab, multiparticulates or osmotic delivery systems, are coated with a mucoadhesive polymeric coating or formed of a mucoadhesive polymer to increase oral bioavailability of Biopharmaceutical Classification System (BCS) Class I drugs. Representative BCS I drugs include valacyclovir, gabapentin, furosemide, levodopa, metformin, and ranitidine HCl. The inclusion of mucoadhesives in the solid oral dosage form brings the dosage form into close proximity with the target epithelium and facilitates diffusion of drug into intestinal tissue. The mucoadhesive polymer may be either dispersed in the matrix of the tablet or applied as a direct compressed coating to the solid oral dosage form. Preferred mucoadhesive polymers include poly(adipic)anhydride “P(AA)” and poly(fumaric-co-sebacic)anhydride “P(FA:SA)”. Other preferred mucoadhesive polymers include non-erodable polymers such as DOPA-maleic anhydride co polymer; isopthalic anhydride polymer; DOPA-methacrylate polymers; and DOPA-cellulosic based polymers.
摘要翻译：固体口服剂型如片剂，迷你片，多颗粒或渗透递送系统用粘膜粘附聚合物涂层或由粘膜粘附聚合物形成以增加生物制药分类系统（BCS）I类药物的口服生物利用度。代表性的BCS I药物包括伐昔洛韦，加巴喷丁，呋塞米，左旋多巴，二甲双胍和盐酸雷尼替丁。在固体口服剂型中包含粘膜粘附剂使剂型与目标上皮紧密接近，并有利于药物扩散到肠组织中。粘膜粘附聚合物可以分散在片剂的基质中，或作为直接压缩包衣施用于固体口服剂型。优选的粘膜粘附聚合物包括聚（己二酸）酐“P（AA）”和聚（富马酸 - 共 - 癸二酸）酐“P（FA：SA）”。其它优选的粘膜粘附聚合物包括不可侵蚀的聚合物，例如DOPA-马来酸酐共聚物; 异烟酸酐聚合物; DOPA-甲基丙烯酸酯聚合物; 和基于DOPA-纤维素的聚合物。

36. 发明申请

US20050276848A1 Sustained release neutralized divalproex sodium 审中-公开
标题翻译：持续释放中和双丙戊酸钠
公开(公告)号：US20050276848A1
公开(公告)日：2005-12-15
申请号：US10867799
申请日：2004-06-15
申请人： Nilobon Podhipleux , Xiu Cheng , Unchalee Lodin , Chih-Ming Chen , Avinash Nangia , Dacheng Tian
发明人： Nilobon Podhipleux , Xiu Cheng , Unchalee Lodin , Chih-Ming Chen , Avinash Nangia , Dacheng Tian
IPC分类号： A61K9/20 , A61K9/22 , A61K9/28 , A61K9/50 , A61K31/19
CPC分类号： A61K9/5078 , A61K9/2886 , A61K31/19
摘要： The present invention is directed to sustained release oral dosage forms comprising neutralized divalproex sodium, methods of manufacturing the dosage forms, and methods of treatment with the dosage forms.
摘要翻译：本发明涉及包含中和的双丙戊酸钠的缓释口服剂型，制备剂型的方法和用剂型治疗的方法。

37. 发明申请

US20050201974A1 Bioadhesive polymers with catechol functionality 审中-公开
标题翻译：具有儿茶酚功能的生物粘合剂聚合物
公开(公告)号：US20050201974A1
公开(公告)日：2005-09-15
申请号：US11009327
申请日：2004-12-09
申请人： Marcus Schestopol , Jules Jacob , Ryan Donnelly , Thomas Ricketts , Avinash Nangia , Edith Mathiowitz , Ze'ev Shaked
发明人： Marcus Schestopol , Jules Jacob , Ryan Donnelly , Thomas Ricketts , Avinash Nangia , Edith Mathiowitz , Ze'ev Shaked
IPC分类号： A61K9/00 , A61K9/20 , A61K31/74 , C08F8/32 , C08G63/91 , C09J135/00 , C09J167/00 , C09J167/04 , C09J201/06
CPC分类号： C08F8/32 , A61K9/0004 , A61K9/006 , A61K9/0065 , A61K9/204 , A61K9/2077 , A61K9/2081 , A61K9/2086 , C08G63/91 , C08G63/912 , C09J167/00 , C09J167/04 , C08F222/06
摘要： Polymers with improved bioadhesive properties and methods for improving bioadhesion of polymers have been developed. A compound containing an aromatic group which contains one or more hydroxyl groups is grafted onto a polymer or coupled to individual monomers. In one embodiment, the polymer is a biodegradable polymer. In another embodiment, the monomers may be polymerized to form any type of polymer, including biodegradable and non-biodegradable polymers. In some embodiments, the polymer is a hydrophobic polymer. In the preferred embodiment, the aromatic compound is catechol or a derivative thereof and the polymer contains reactive functional groups. In the most preferred embodiment, the polymer is a polyanhydride and the aromatic compound is the catechol derivative, DOPA. These materials display bioadhesive properties superior to conventional bioadhesives used in therapeutic and diagnostic applications. These bioadhesive materials can be used to fabricate new drug delivery or diagnostic systems with increased residence time at tissue surfaces, and consequently increase the bioavailability of a drug or a diagnostic agent. In a preferred embodiment, the bioadhesive material is a coating on a controlled release oral dosage formulation and/or forms a matrix in an oral dosage formulation.
摘要翻译：已经开发了具有改进的生物粘附性质的聚合物和改善聚合物生物粘附的方法。含有含有一个或多个羟基的芳族基团的化合物被接枝到聚合物上或与单独的单体偶联。在一个实施方案中，聚合物是可生物降解的聚合物。在另一个实施方案中，单体可以聚合以形成任何类型的聚合物，包括可生物降解和不可生物降解的聚合物。在一些实施方案中，聚合物是疏水性聚合物。在优选的实施方案中，芳族化合物是儿茶酚或其衍生物，并且聚合物含有反应性官能团。在最优选的实施方案中，聚合物是聚酐，芳族化合物是邻苯二酚衍生物DOPA。这些材料显示出比用于治疗和诊断应用的常规生物粘合剂优越的生物粘附性。这些生物粘附材料可用于制造具有增加的组织表面停留时间的新药物递送或诊断系统，并因此提高药物或诊断剂的生物利用度。在优选的实施方案中，生物粘附材料是在控释口服剂量制剂上的涂层和/或在口服剂量制剂中形成基质。

38. 发明授权

US5196190A Synthetic skin substitutes 失效
标题翻译：合成皮肤替代品
公开(公告)号：US5196190A
公开(公告)日：1993-03-23
申请号：US607128
申请日：1990-10-03
申请人： Avinash Nangia , Cheung-Tak Hung
发明人： Avinash Nangia , Cheung-Tak Hung
IPC分类号： A61F13/00 , A61L15/22
CPC分类号： A61F13/00063 , A61L15/225 , A61L27/60 , A61F13/069 , A61F2013/00157 , A61F2013/00519 , A61F2013/00527 , A61F2013/0091 , A61F2013/00927
摘要： Membranes suitable for use as wound dressings and in particular as synthetic skin substitutes are disclosed. The membranes consist of a natural or synthetic polymer, a non-gellable polysaccharide and a cross-linking agent.The membranes of the invention may contain one or more additional components selected from water-loss control agents, emulsifying agents and plasticizers. An internal reinforcing material may also be provided to supplement the inherent mechanical strength of the membrane.Methods of forming such membranes are also disclosed.
摘要翻译：公开了适用于伤口敷料，特别是合成皮肤替代物的膜。膜由天然或合成聚合物，不可凝胶多糖和交联剂组成。本发明的膜可以含有一种或多种选自失水控制剂，乳化剂和增塑剂的其它组分。还可以提供内部增强材料以补充膜的固有的机械强度。还公开了形成这种膜的方法。

39. 发明申请

US20110262538A1 NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE 有权
标题翻译：含有双胍和噻唑烷二酮衍生物的新型药用配方
公开(公告)号：US20110262538A1
公开(公告)日：2011-10-27
申请号：US13151653
申请日：2011-06-02
申请人： Unchalee Kositprapa , Robert I. Goldfarb , John R. Cardinal , Avinash Nangia
发明人： Unchalee Kositprapa , Robert I. Goldfarb , John R. Cardinal , Avinash Nangia
IPC分类号： A61K31/4439 , A61P3/10 , A61K9/28
CPC分类号： A61K9/209 , A61K9/0002 , A61K9/0004 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/282 , A61K9/2866 , A61K31/155 , A61K31/425 , A61K31/426 , A61K31/4439 , A61K45/06 , Y10S514/866 , A61K2300/00
摘要： A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
摘要翻译：本文公开和描述了包含与包含噻唑烷二酮衍生物的第二组分组合的抗高血糖药物的控释组分的药物剂型。

40. 发明申请

US20100323010A1 FORMULATION AND PROCESS FOR DRUG LOADED CORES 审中-公开
标题翻译：药物装载的配方和工艺
公开(公告)号：US20100323010A1
公开(公告)日：2010-12-23
申请号：US12853820
申请日：2010-08-10
申请人： Mongkol Sriwongjanya , Samuel Yuk , Avinash Nangia
发明人： Mongkol Sriwongjanya , Samuel Yuk , Avinash Nangia
IPC分类号： A61K9/22 , A61K31/138 , A61P9/12
CPC分类号： A61K9/1676 , A61K9/2077 , A61K31/00 , A61K31/137
摘要： The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core.
摘要翻译：本发明涉及美托洛尔及其药学上可接受的盐的控释丸，其使用水溶性或水溶胀性惰性起始种子或核心。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式